JP2024015120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024015120A5 JP2024015120A5 JP2023202765A JP2023202765A JP2024015120A5 JP 2024015120 A5 JP2024015120 A5 JP 2024015120A5 JP 2023202765 A JP2023202765 A JP 2023202765A JP 2023202765 A JP2023202765 A JP 2023202765A JP 2024015120 A5 JP2024015120 A5 JP 2024015120A5
- Authority
- JP
- Japan
- Prior art keywords
- plinabulin
- hours
- administration
- administering
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025234643A JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625290P | 2018-02-01 | 2018-02-01 | |
| US62/625,290 | 2018-02-01 | ||
| US201862713486P | 2018-08-01 | 2018-08-01 | |
| US62/713,486 | 2018-08-01 | ||
| US201862749060P | 2018-10-22 | 2018-10-22 | |
| US62/749,060 | 2018-10-22 | ||
| US201862757648P | 2018-11-08 | 2018-11-08 | |
| US62/757,648 | 2018-11-08 | ||
| JP2020541924A JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| PCT/US2019/015867 WO2019152530A1 (en) | 2018-02-01 | 2019-01-30 | Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541924A Division JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025234643A Division JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024015120A JP2024015120A (ja) | 2024-02-01 |
| JP2024015120A5 true JP2024015120A5 (enExample) | 2024-05-27 |
Family
ID=67479904
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541924A Pending JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2023202765A Pending JP2024015120A (ja) | 2018-02-01 | 2023-11-30 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541924A Pending JP2021512121A (ja) | 2018-02-01 | 2019-01-30 | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025234643A Pending JP2026026377A (ja) | 2018-02-01 | 2025-12-05 | プリナブリンおよびｇ－ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030843A1 (enExample) |
| EP (1) | EP3746076A4 (enExample) |
| JP (3) | JP2021512121A (enExample) |
| KR (2) | KR20200116477A (enExample) |
| CN (1) | CN112105363A (enExample) |
| AU (1) | AU2019216305B2 (enExample) |
| BR (1) | BR112020015758A2 (enExample) |
| CA (1) | CA3089391A1 (enExample) |
| IL (1) | IL276197A (enExample) |
| SG (1) | SG11202006990TA (enExample) |
| WO (1) | WO2019152530A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| MX376122B (es) | 2015-07-13 | 2025-03-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina. |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (pt) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| EP3576733A4 (en) | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | NEUTROPENIA REDUCTION METHOD |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11267858B2 (en) | 2019-05-31 | 2022-03-08 | Spectrum Pharmaceuticals, Inc. | Methods of treatment using G-CSF protein complex |
| US11684655B2 (en) | 2019-05-31 | 2023-06-27 | Spectrum Pharmaceuticals, Inc. | Methods of treating neutorpenia using G-CSF protein complex |
| US20240299377A1 (en) * | 2019-10-15 | 2024-09-12 | Beyondspring Pharmaceuticals, Inc. | Methods and compositions for treating iron disorders |
| JP2023505506A (ja) * | 2019-12-05 | 2023-02-09 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 化学療法または放射線療法で誘導された好中球減少症を治療する方法 |
| WO2022015710A1 (en) * | 2020-07-17 | 2022-01-20 | Spectrum Pharmaceuticals, Inc. | Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| KR102375269B1 (ko) * | 2021-01-27 | 2022-03-17 | 한미약품 주식회사 | 단백질 액상 제제 및 이의 제조방법 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| FI131561B1 (en) * | 2023-12-28 | 2025-06-30 | Faron Pharmaceuticals Oy | CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2749786A1 (en) * | 2009-01-16 | 2010-07-22 | Jason Benjamin Bock | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein |
| ES2902665T3 (es) * | 2013-10-11 | 2022-03-29 | Beyondspring Inc | Tratamiento del cáncer con combinación de plinabulina y taxano |
| BR112018074990A2 (pt) * | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
| EP3576733A4 (en) * | 2017-02-01 | 2020-11-25 | Beyondspring Pharmaceuticals, Inc. | NEUTROPENIA REDUCTION METHOD |
-
2019
- 2019-01-30 CN CN201980018772.9A patent/CN112105363A/zh active Pending
- 2019-01-30 BR BR112020015758-9A patent/BR112020015758A2/pt unknown
- 2019-01-30 AU AU2019216305A patent/AU2019216305B2/en active Active
- 2019-01-30 CA CA3089391A patent/CA3089391A1/en active Pending
- 2019-01-30 JP JP2020541924A patent/JP2021512121A/ja active Pending
- 2019-01-30 KR KR1020207024515A patent/KR20200116477A/ko not_active Ceased
- 2019-01-30 KR KR1020267003258A patent/KR20260023097A/ko active Pending
- 2019-01-30 EP EP19746727.7A patent/EP3746076A4/en active Pending
- 2019-01-30 WO PCT/US2019/015867 patent/WO2019152530A1/en not_active Ceased
- 2019-01-30 SG SG11202006990TA patent/SG11202006990TA/en unknown
- 2019-01-30 US US16/966,156 patent/US20210030843A1/en active Pending
-
2020
- 2020-07-21 IL IL276197A patent/IL276197A/en unknown
-
2023
- 2023-11-30 JP JP2023202765A patent/JP2024015120A/ja active Pending
-
2025
- 2025-12-05 JP JP2025234643A patent/JP2026026377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024015120A5 (enExample) | ||
| Livingston et al. | Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study | |
| JP2020514412A5 (enExample) | ||
| JPWO2019152530A5 (enExample) | ||
| Somlo et al. | High‐dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high‐risk primary breast cancer | |
| CA2435921A1 (en) | Method of cancer therapy | |
| Sorrentino et al. | Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models | |
| CN118526513A (zh) | 紫花前胡苷在制备减轻铂类药物肌毒性的药物中的应用 | |
| CN118845664A (zh) | 盐酸米托蒽醌脂质体在治疗骨与软组织肉瘤中的用途 | |
| RU2010139840A (ru) | Комбинация противораковых агентов | |
| CN113893279B (zh) | 一清颗粒与环磷酰胺联合用药在抗肿瘤治疗药物中的应用 | |
| EP4681723A1 (en) | Pharmaceutical composition for treating triple-negative breast cancer | |
| JPWO2020112765A5 (enExample) | ||
| CN105769849B (zh) | 一种治疗卵巢癌的药物组合物 | |
| CN117883432B (zh) | 丹酚酸b的新用途 | |
| Wolf | Dose intensive chemotherapy in small cell lung cancer | |
| CN105833173B (zh) | 冬凌草甲素联合姜黄素在制备白血病治疗药物中的应用 | |
| CN115120671B (zh) | 一种治疗缓慢性心律失常的中药组合物及其应用 | |
| Choy et al. | Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer | |
| CN102872043B (zh) | Gypensapogenin B在升高白细胞的药物中的应用 | |
| Natale | Chemotherapy in small cell lung cancer: the current state of the art | |
| CN103860561B (zh) | 一种防治乳腺癌的药物组合物及其应用 | |
| JPWO2022150628A5 (enExample) | ||
| CN111388665A (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN116947942A (zh) | 一类单萜化合物用于结直肠肿瘤治疗的用途 |